Randomised trials in cardiovascular and metabolic disease
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
The aim of this programme is to demonstrate reliably any benefits of treatments that can be widely used in common diseases such as heart disease, diabetes and kidney disease. Even quite modest improvements in outcome in common conditions can lead to important benefits for patients. In order to be sure that treatments really work, large numbers of people usually need to be given the treatment and compared with similar people not given the treatment. The most reliable way to do this is using randomisation, a method whereby the decision about who receives a treatment is determined by chance (like tossing a coin). In order to help provide reliable results, these randomised trials also often involve masking (or blinding) the treatment so that neither the participants nor their doctors or nurses know if they are taking an active or dummy treatment. Over the past several years, we have pioneered ways of running randomised trials involving thousands of people efficiently and cost-effectively to gain reliable information. We have developed a wide experience of using IT and centrally-held health records to streamline the running of large trials. Ongoing studies include testing a cholesterol-lowering drug added to statin therapy in people at high risk of heart problems, a new treatment for kidney disease and testing an established medication to investigate whether it can slow the worsening of eye disease in people with diabetes.
Technical Summary
This programme aims to generate reliable evidence about interventions with potential for significant public health benefit. Treatments with even modest effects in common diseases (such as vascular disease, diabetes or chronic kidney disease) may make significant contributions to reducing morbidity and mortality globally. Building on epidemiological evidence and other data generated in PHRU, CTSU and elsewhere, we aim to deliver large-scale randomised evidence to determine the efficacy and safety of treatments in cardiovascular and metabolic disease. Along with smoking and blood pressure, blood lipids are a major cause of cardiovascular disease, a major cause of morbidity and mortality worldwide. Higher levels of LDL cholesterol and lower levels of HDL cholesterol are associated with higher risks of coronary heart disease. Partly as a result of our large randomised trials (HPS, SEARCH and SHARP) and meta-analyses, statins, which effectively lower LDL cholesterol, are now very widely used for both primary and secondary prevention of cardiovascular disease. However some patients remain at high risk despite statin use, thus additional safe treatments to modify risk are needed. Attention is now turning to newer drugs which modulate lipids by other mechanisms. The effects of such treatments on top of statins are likely to be modest, so large-scale randomised evidence is required to assess their effects reliably, hence the ORION-4 trial of a silencing RNA to PCSK9 (inclisiran) will recruit 15,000 people at high risk of cardiovascular disease. Participants will receive 6-monthly injections of inclisiran or placebo and be followed for at least 5 years at large streamlined clinics based in the UK and USA. Recent trials of sodium glucose co-transporter 2 inhibitors (SGLT2i) have shown they reduce the risk of cardiovascular disease (in particular heart failure) and progression of kidney disease among patients with diabetes. The mechanism by which SGLT2i affect kidney function does not require the presence of diabetes, so an important question in nephrology is whether SGLT2i also reduce the risk of cardiovascular disease and progression of kidney disease among patients with established chronic kidney disease, regardless of whether they have diabetes or not. The EMPA-KIDNEY trial will recruit at least 5000 participants with chronic kidney disease (at least a third with and a third without diabetes) and compare the effect of empagliflozin 10 mg daily versus placebo on a cardiorenal primary outcome. The LENS trial is also comparing an established treatment (fenofibrate) among participants with diabetic eye disease to test the hypothesis (raised by other trials) that fenofibrate may delay the progression of retinopathy.
Over the last several years, PHRU has developed streamlined methods to recruit large numbers of patients and conduct trials efficiently as well as cost-effectively (e.g. ASCEND), including using record linkage to facilitate follow-up, both during the trials (e.g. ASCEND, 3C, LENS) and in the longer-term (e.g. HPS, SEARCH). Such efforts will continue in the next quinquennium (including using the ongoing trials as laboratories for such methodological development) so that the outputs from this programme will not only be reliable answers to important questions in the treatment of cardiovascular and metabolic disease, but also rapidly transferable information on how to conduct such trials for use by the wider trials community.
Over the last several years, PHRU has developed streamlined methods to recruit large numbers of patients and conduct trials efficiently as well as cost-effectively (e.g. ASCEND), including using record linkage to facilitate follow-up, both during the trials (e.g. ASCEND, 3C, LENS) and in the longer-term (e.g. HPS, SEARCH). Such efforts will continue in the next quinquennium (including using the ongoing trials as laboratories for such methodological development) so that the outputs from this programme will not only be reliable answers to important questions in the treatment of cardiovascular and metabolic disease, but also rapidly transferable information on how to conduct such trials for use by the wider trials community.
Organisations
- University of Oxford (Lead Research Organisation)
- NHS England (Collaboration)
- North Ormesby Health Village (Collaboration)
- Doncaster and Bassetlaw Hospitals NHS Foundation Trust (Collaboration)
- Mid Yorkshire Hospitals NHS Trust (Collaboration)
- Flu Lab (Collaboration)
- Mylan (Collaboration)
- John Radcliffe Hospital (Collaboration)
- Birmingham Heartlands Hospital (Collaboration)
- Farnham Hospital (Collaboration)
- HEALTH INTELLIGENCE LTD (Collaboration)
- Public Health Wales NHS Trust (Collaboration)
- NHS Scotland (Collaboration)
- Glenfield Hospital (Collaboration)
- King's Mill Hospital (Collaboration)
- Roche Pharmaceuticals (Collaboration)
- Eagle Bridge Health and Wellbeing Centre (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Bexhill Hospital (Collaboration)
- MOORFIELDS EYE HOSPITAL (Collaboration)
- Gloucestershire Royal Hospital (Collaboration)
- Associazione Nazionale Medici Cardiologi Ospedalieri (Collaboration)
- Homerton University Hospital (Collaboration)
- PUBLIC HEALTH ENGLAND (Collaboration)
- Northgate Public Services (Collaboration)
- Norfolk and Norwich University Hospitals NHS Foundation Trust (Collaboration)
- Hertford County Hospital (Collaboration)
- National Institute for Health Research (Collaboration)
- Duke University (Collaboration)
- Hull Royal Infirmary (Collaboration)
- Regeneron Pharmaceuticals, Inc. (Collaboration)
- Boehringer Ingelheim (Collaboration)
- University of Würzburg (Collaboration)
- UNIVERSITY OF BRITISH COLUMBIA (Collaboration)
Publications
Haynes R
(2020)
Chronic kidney disease, heart failure and neprilysin inhibition.
in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Herrington W
(2023)
Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection
in Kidney International Reports
Herrington W
(2021)
Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors
in European Journal of Heart Failure
Herrington WG
(2020)
Kidney disease trials for the 21st century: innovations in design and conduct.
in Nature reviews. Nephrology
Hopewell JC
(2020)
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom.
in European heart journal
Related Projects
Project Reference | Relationship | Related To | Start | End | Award Value |
---|---|---|---|---|---|
MC_UU_00017/1 | 31/03/2019 | 31/03/2024 | £5,782,000 | ||
MC_UU_00017/2 | Transfer | MC_UU_00017/1 | 31/03/2019 | 31/03/2024 | £2,644,000 |
MC_UU_00017/3 | Transfer | MC_UU_00017/2 | 31/03/2019 | 31/03/2024 | £3,269,000 |
MC_UU_00017/4 | Transfer | MC_UU_00017/3 | 31/03/2019 | 31/03/2024 | £1,831,000 |
MC_UU_00017/5 | Transfer | MC_UU_00017/4 | 31/03/2019 | 31/03/2024 | £2,183,000 |
Description | Consultation on UK regulations for clinical trials |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Impact | Decisions are yet to be made so no immediate changes. |
Description | European Renal & Cardiovascular Medicine (EURECA-m) & European Renal Best Practice (ERBP) working groups of the European Renal Association (ERA) |
Geographic Reach | Europe |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Co-author. Updated consensus statement on SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic kidney disease: European Renal & Cardiovascular Medicine (EURECA-m) & European Renal Best Practice (ERBP) working groups of the European Renal Association (ERA) |
Description | Global marketing approvals of empagliflozin for use in adults with chronic kidney disease |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in other policy documents |
Impact | Major impact of EMPA-KIDNEY trial results |
URL | https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance |
Description | ICH Good Clinical Practice E6(R3) consultation |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | R3 is not finalised yet so changes not yet material. |
URL | https://www.ich.org/news/ich-e6r3-draft-guideline-reaches-step-2-ich-process |
Guideline Title | WHO COVID-19 guidelines |
Description | Influence on international treatment guidelines for COVID-19 |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Impact | It has been estimated that implementation of RECOVERY dexamethasone result has saved over 1000000 lives globally. - dexamethasone, tocilizumab and baricitinib all now recommended in international (WHO) and national guidelines for treatment of covid - RECOVERY data submitted to FDA and led to FDA licensing tocilizumab for treatment of covid (similar in 34 other countries) |
Description | MHRA Cardiac, Diabetes, Renal, Respiratory, Allergy (CDDRA) Expert Advisory Group expert member |
Geographic Reach | National |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | monthly advisory group to MHRA |
URL | https://www.gov.uk/government/organisations/commission-on-human-medicines/about/membership#cardiovas... |
Description | NICE approval for use of empagliflozin in adults with CKD in the UK (ta942) |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Impact | 1 Recommendations Why these recommendations were made 1.1 Empagliflozin is recommended as an option for treating chronic kidney disease (CKD) in adults, only if: it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and people have an estimated glomerular filtration rate of: 20 ml/min/1.73 m2 to less than 45 ml/min/1.73 m2 or 45 ml/min/1.73 m2 to 90 ml/min/1.73 m2 and either: a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more, or type 2 diabetes. 1.2 If people with the condition and their clinicians consider empagliflozin to be 1 of a range of suitable treatments (including dapagliflozin), after discussing the advantages and disadvantages of all the options, use the least expensive. Take account of administration costs, dosage, price per dose and commercial arrangements 1.3 This recommendation is not intended to affect treatment with empagliflozin that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Why these recommendations were made Management of CKD aims to slow its progression. Standard care is lifestyle and dietary changes, and usually ACE inhibitors or ARBs. Empagliflozin is an oral treatment for CKD. The company proposes that empagliflozin would be used as an add-on to optimised standard care with ACE inhibitors or ARBs. Some people take dapagliflozin as an add-on to standard care. The company proposes that empagliflozin would be used in a similar but slightly broader population to dapagliflozin. This does not include everyone who it is licensed for. Clinical trial evidence suggests that empagliflozin plus standard care is more effective than standard care alone. But the main clinical trial did not include people with CKD with an estimated glomerular filtration rate of less than 20 ml/min/1.73 m2. And people with an estimated glomerular filtration rate between 45 ml/min/1.73 m2 and 90 ml/min/1.73 m2 were only included if they also had a urine albumin-to-creatinine ratio of 22.6 g/mmol or more. There are no clinical trials directly comparing empagliflozin with dapagliflozin in people with CKD. Results of an indirect comparison suggest that empagliflozin has a similar effectiveness to dapagliflozin, and it likely has similar safety. CKD can progress more quickly in some ethnic minority groups and, in people with type 2 diabetes, it progresses more quickly in people under 55. This was acknowledged but could not be considered in the decision making. The cost-effectiveness estimates for empagliflozin compared with standard care are within the range NICE normally considers an acceptable use of NHS resources. Also, a cost comparison suggests that empagliflozin has similar costs to dapagliflozin. So, empagliflozin is recommended. |
URL | https://www.nice.org.uk/guidance/TA942/chapter/1-Recommendations |
Description | RECOVERY Trial |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Influenced training of practitioners or researchers |
Impact | The RECOVERY Trial investigates treatments to tackle COVID-19. It is the world's largest such trail and since it began in 2020, it has produced definitive results for a number of treatments that have informed clinical practice around the world. As a result, the deadly impact of COVID has dramatically reduced. |
URL | http://www.recoverytrial.net |
Description | Task Force member of 2023 European Society of Cardiology Guidelines for the management of cardiovascular disease in patients with diabetes. |
Geographic Reach | Europe |
Policy Influence Type | Participation in a guidance/advisory committee |
Impact | Major international clinical practice guideline endorsed by the following societies: Armenian Cardiologists Association , Azerbaijan Society of Cardiology , Belgian Society of Cardiology , British Cardiovascular Society , Association of Cardiologists of Bosnia & Herzegovina , Croatian Cardiac Society , Egyptian Society of Cardiology , Estonian Society of Cardiology , Finnish Cardiac Society , French Society of Cardiology , Georgian Society of Cardiology , German Cardiac Society , Hellenic Society of Cardiology , Hungarian Society of Cardiology , Irish Cardiac Society , Italian Federation of Cardiology , Kosovo Society of Cardiology , Kyrgyz Society of Cardiology , Lithuanian Society of Cardiology , Luxembourg Society of Cardiology , Maltese Cardiac Society , Moroccan Society of Cardiology , Polish Cardiac Society , Portuguese Society of Cardiology , San Marino Society of Cardiology , Cardiology Society of Serbia , Slovak Society of Cardiology , Spanish Society of Cardiology , Swiss Society of Cardiology , Turkish Society of Cardiology |
URL | https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/CVD-and-Diabetes-Guidelines |
Description | Updated consensus statement on SGLT2i |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Aldosterone Synthase Inhibitor trial in CKD (start-up agreement) |
Amount | £1,800,000 (GBP) |
Organisation | Boehringer Ingelheim |
Sector | Private |
Country | Germany |
Start |
Description | DPhil studentship funding awarded to study genetic of chronic kidney disease progression: Dr Killian Donovan |
Amount | £251,000 (GBP) |
Organisation | Kidney Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | EASi-KIDNEY trial (Chief Investigator) |
Amount | £171,000,000 (GBP) |
Organisation | Boehringer Ingelheim |
Sector | Private |
Country | Germany |
Start | 03/2023 |
Description | EMPA-KIDNEY Post-trial follow-up (Chief Investigator, 2022-2025) |
Amount | £5,600,000 (GBP) |
Organisation | Boehringer Ingelheim |
Sector | Private |
Country | Germany |
Start | 06/2021 |
End | 12/2025 |
Description | EMPA-KIDNEY Tubular biomarker analyses (Chief Investigator, 2022-2024) |
Amount | £575,000 (GBP) |
Organisation | Boehringer Ingelheim |
Sector | Private |
Country | Germany |
Start | 01/2022 |
End | 12/2024 |
Description | RECOVERY Influenza |
Amount | £11,416,263 (GBP) |
Organisation | National Philanthropic Trust |
Sector | Charity/Non Profit |
Country | United States |
Start | 11/2022 |
End | 06/2026 |
Description | RECOVERY/Phase 2 Therapeutic Trials Reconfiguration |
Amount | £17,999,777 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2020 |
End | 11/2022 |
Title | Additional file 2 of Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial |
Description | Additional file 2. Analysis dataset containing all the information needed to replicate this analysis, with one row per person. |
Type Of Material | Database/Collection of data |
Year Produced | 2023 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_2_of_Effect_of_low-dose_aspirin... |
Title | Additional file 2 of Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial |
Description | Additional file 2. Analysis dataset containing all the information needed to replicate this analysis, with one row per person. |
Type Of Material | Database/Collection of data |
Year Produced | 2023 |
Provided To Others? | Yes |
URL | https://springernature.figshare.com/articles/dataset/Additional_file_2_of_Effect_of_low-dose_aspirin... |
Title | RECOVERY trial datasets |
Description | The RECOVERY trial has collected data on >48000 people with severe covid. These data have been curated into individual datasets of each comparison within the trial and are being made available to external bona fide researchers. |
Type Of Material | Database/Collection of data |
Year Produced | 2023 |
Provided To Others? | Yes |
Impact | No publications have yet emerged from these datasets, but we anticipate this will start this year. |
URL | https://www.iddo.org/covid19/data-sharing/accessing-data |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Bexhill Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Birmingham Heartlands Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Doncaster and Bassetlaw Hospitals NHS Foundation Trust |
Department | Diabetes & Endocrine Centre, Doncaster Royal Infirmary |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Eagle Bridge Health and Wellbeing Centre |
Country | United Kingdom |
Sector | Public |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Farnham Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Glenfield Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Gloucestershire Royal Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Hertford County Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Homerton University Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Hull Royal Infirmary |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | John Radcliffe Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | King's Mill Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Mid Yorkshire Hospitals NHS Trust |
Country | United Kingdom |
Sector | Public |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Moorfields Eye Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | NHS England |
Country | United Kingdom |
Sector | Public |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Norfolk and Norwich University Hospitals NHS Foundation Trust |
Country | United Kingdom |
Sector | Public |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | North Ormesby Health Village |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Northgate Public Services |
Country | United Kingdom |
Sector | Private |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Public Health England |
Department | Bristol and Weston Diabetic Eye Screening Programme |
Country | United Kingdom |
Sector | Public |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | ASCEND-Eye Diabetic Eye Screening Programme |
Organisation | Public Health Wales NHS Trust |
Country | United Kingdom |
Sector | Public |
PI Contribution | The ASCEND-Eye study will use linked data from the NHS Diabetic Eye Screening Programme (DESP) to determine whether aspirin or omega-3 fatty acids alter the course of diabetic retinopathy or diabetic maculopathy. Each partnering DESP is facilitating the data linkage by identifying appropriate staff to run a query on their local database, or to facilitate the software provider to extract data on their behalf. |
Collaborator Contribution | academic collaboration |
Impact | n/a |
Start Year | 2019 |
Description | EMPA Kidney regional coordinating centres |
Organisation | Associazione Nazionale Medici Cardiologi Ospedalieri |
Country | Italy |
Sector | Charity/Non Profit |
PI Contribution | 1. Duke Clinical Research Institute, Durham USA: DCRI is the US Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to DCRI. DCRI coordinates all activities for the trial in the US including management of 55 clinical centres and recruitment of 1250 participants. This collaboration began in 2018 and is ongoing. 2. University of British Columbia, Vancouver Canada. UBC is the US Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to UBC. UBC coordinates all activities for the trial in the US including management of 20 clinical centres and recruitment of 500 participants. This collaboration began in 2018 and is ongoing. 3. University of Wurzburg, Wurzburg Germany. UW is the German Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to UW. UW coordinates all activities for the trial in Germany including management of 35 clinical centres and recruitment of 1250 participants. This collaboration began in 2018 and is ongoing. 4. National Centre for CKD Research, Nanjing China. Nanjing is part of the China Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to Nanjing. Nanjing coordinates all activities for the trial in China including management of 25 clinical centres and recruitment of 1000 participants. This collaboration began in 2018 and is ongoing. 5. Associazione Nazionale Medici Cardiologi Ospedalieri which we have a contract with to deliver EMPA-KIDNEY in Italy. ANMCO is overseeing about 20 sites. |
Collaborator Contribution | research collaboration |
Impact | 2020-recruitment phase |
Start Year | 2019 |
Description | EMPA Kidney regional coordinating centres |
Organisation | Duke University |
Department | Duke Clinical Research Institute |
Country | United States |
Sector | Academic/University |
PI Contribution | 1. Duke Clinical Research Institute, Durham USA: DCRI is the US Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to DCRI. DCRI coordinates all activities for the trial in the US including management of 55 clinical centres and recruitment of 1250 participants. This collaboration began in 2018 and is ongoing. 2. University of British Columbia, Vancouver Canada. UBC is the US Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to UBC. UBC coordinates all activities for the trial in the US including management of 20 clinical centres and recruitment of 500 participants. This collaboration began in 2018 and is ongoing. 3. University of Wurzburg, Wurzburg Germany. UW is the German Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to UW. UW coordinates all activities for the trial in Germany including management of 35 clinical centres and recruitment of 1250 participants. This collaboration began in 2018 and is ongoing. 4. National Centre for CKD Research, Nanjing China. Nanjing is part of the China Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to Nanjing. Nanjing coordinates all activities for the trial in China including management of 25 clinical centres and recruitment of 1000 participants. This collaboration began in 2018 and is ongoing. 5. Associazione Nazionale Medici Cardiologi Ospedalieri which we have a contract with to deliver EMPA-KIDNEY in Italy. ANMCO is overseeing about 20 sites. |
Collaborator Contribution | research collaboration |
Impact | 2020-recruitment phase |
Start Year | 2019 |
Description | EMPA Kidney regional coordinating centres |
Organisation | University of British Columbia |
Country | Canada |
Sector | Academic/University |
PI Contribution | 1. Duke Clinical Research Institute, Durham USA: DCRI is the US Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to DCRI. DCRI coordinates all activities for the trial in the US including management of 55 clinical centres and recruitment of 1250 participants. This collaboration began in 2018 and is ongoing. 2. University of British Columbia, Vancouver Canada. UBC is the US Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to UBC. UBC coordinates all activities for the trial in the US including management of 20 clinical centres and recruitment of 500 participants. This collaboration began in 2018 and is ongoing. 3. University of Wurzburg, Wurzburg Germany. UW is the German Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to UW. UW coordinates all activities for the trial in Germany including management of 35 clinical centres and recruitment of 1250 participants. This collaboration began in 2018 and is ongoing. 4. National Centre for CKD Research, Nanjing China. Nanjing is part of the China Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to Nanjing. Nanjing coordinates all activities for the trial in China including management of 25 clinical centres and recruitment of 1000 participants. This collaboration began in 2018 and is ongoing. 5. Associazione Nazionale Medici Cardiologi Ospedalieri which we have a contract with to deliver EMPA-KIDNEY in Italy. ANMCO is overseeing about 20 sites. |
Collaborator Contribution | research collaboration |
Impact | 2020-recruitment phase |
Start Year | 2019 |
Description | EMPA Kidney regional coordinating centres |
Organisation | University of Wurzburg |
Country | Germany |
Sector | Academic/University |
PI Contribution | 1. Duke Clinical Research Institute, Durham USA: DCRI is the US Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to DCRI. DCRI coordinates all activities for the trial in the US including management of 55 clinical centres and recruitment of 1250 participants. This collaboration began in 2018 and is ongoing. 2. University of British Columbia, Vancouver Canada. UBC is the US Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to UBC. UBC coordinates all activities for the trial in the US including management of 20 clinical centres and recruitment of 500 participants. This collaboration began in 2018 and is ongoing. 3. University of Wurzburg, Wurzburg Germany. UW is the German Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to UW. UW coordinates all activities for the trial in Germany including management of 35 clinical centres and recruitment of 1250 participants. This collaboration began in 2018 and is ongoing. 4. National Centre for CKD Research, Nanjing China. Nanjing is part of the China Regional Coordinating Centre for EMPA-KIDNEY paid by a grant from University of Oxford to Nanjing. Nanjing coordinates all activities for the trial in China including management of 25 clinical centres and recruitment of 1000 participants. This collaboration began in 2018 and is ongoing. 5. Associazione Nazionale Medici Cardiologi Ospedalieri which we have a contract with to deliver EMPA-KIDNEY in Italy. ANMCO is overseeing about 20 sites. |
Collaborator Contribution | research collaboration |
Impact | 2020-recruitment phase |
Start Year | 2019 |
Description | FLULAB funding for RECOVERY |
Organisation | Flu Lab |
Sector | Charity/Non Profit |
PI Contribution | funding for RECOVERY trial to expand to assess treatments for severe influenza in UK and abroad. |
Collaborator Contribution | funding for RECOVERY trial to expand to assess treatments for severe influenza in UK and abroad. |
Impact | n/a |
Start Year | 2022 |
Description | Health Intelligence Limited |
Organisation | Health Intelligence Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | Health Intelligence Ltd did not request payment for the script development or data processing. |
Collaborator Contribution | Northgate linked NHS Diabetic Eye Screening data for 11 collaborating DESPs. Those DESPs were: BER Berkshire DESP BRI Bristol and Weston DESP DEV Devon DESP DOR Dorset DESP EAN East Anglia DESP ESX Essex DESP GMN Greater Manchester North DESP GMS Greater Manchester South DESP HIW Hampshire and Isle of Wight NWL North West London DESP PCT Kent and Medway DESP |
Impact | Analyses of all DESP linkage data received are ongoing. Data sharing agreement produced with the input of UnioOx Research Services. Fully executed: 23rd August 2021 |
Start Year | 2020 |
Description | LENS Trial |
Organisation | Mylan |
Country | Global |
Sector | Private |
PI Contribution | conduct of LENS trial |
Collaborator Contribution | Mylan - provision of study treatment (placebo and fenofibrate) NHS Scotland - (i) provision of pseudonymised data for follow up (ii) data to allow invitation of participants |
Impact | n/a |
Start Year | 2019 |
Description | LENS Trial |
Organisation | NHS Scotland |
Country | United Kingdom |
Sector | Public |
PI Contribution | conduct of LENS trial |
Collaborator Contribution | Mylan - provision of study treatment (placebo and fenofibrate) NHS Scotland - (i) provision of pseudonymised data for follow up (ii) data to allow invitation of participants |
Impact | n/a |
Start Year | 2019 |
Description | Northgate Public Services Limited |
Organisation | Northgate Public Services |
Country | United Kingdom |
Sector | Private |
PI Contribution | £18,850 was paid to Northgate for the linkage script development and data processing. This was funded by a BHF CRE awarded to E Sammons. |
Collaborator Contribution | Northgate linked NHS Diabetic Eye Screening data for 15 collaborating DESPs. Those DESPs were: BSW Bath NE Somerset Swindon and Wiltshire DESP SUR Surrey DESP SWL South West London DESP HER Arden Herefordshire and Worcestershire DESP NTG North of Tyne and Gateshead DESP MER Central Mersey WRC West Riding and Craven DESP ENH East and North Hertfordshire HUM Humber DESP OXF Oxfordshire DESP SES South East Sussex DESP CHS Cheshire DESP NNT North Nottinghamshire NOT Greater Nottingham YOR North Yorkshire DESP |
Impact | Analyses of all DESP linkage data received are ongoing. A Contract for Professional Services was produced with the input of UnioOx Research Services which outlined the development of a linkage script and the data processing relationship relevant to the data transfers. Fully executed: 27th January 2020 |
Start Year | 2019 |
Description | RECOVERY Trial |
Organisation | National Institute for Health Research |
Department | NIHR Clinical Research Network (CRN) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | RECOVERY collaborates with NIHR Clinical Research Network who provide staff at many of the hospitals in England and assist with delivery; NHS Blood & Transplant who collected and distributed convalescent plasma for that comparison; Roche (who provided tocilizumab but no funding); Regeneron (who provided REGN-COV2 but no funding); |
Collaborator Contribution | RECOVERY collaborates with NIHR Clinical Research Network who provide staff at many of the hospitals in England and assist with delivery; NHS Blood & Transplant who collected and distributed convalescent plasma for that comparison; Roche (who provided tocilizumab but no funding); Regeneron (who provided REGN-COV2 but no funding); |
Impact | An understanding of the treatments that are effective, or not effective, on COVID-19 |
Start Year | 2020 |
Description | RECOVERY-GSK/Vir |
Organisation | GlaxoSmithKline (GSK) |
Country | Global |
Sector | Private |
PI Contribution | Randomised assessment of sotrovimab in patients with severe COVID-19 |
Collaborator Contribution | Provision of sotrovimab free of charge to sites |
Impact | None to date; trial ongoing. |
Start Year | 2021 |
Description | RECOVERY-Regeneron |
Organisation | Regeneron Pharmaceuticals, Inc. |
Country | United States |
Sector | Private |
PI Contribution | Randomised assessment of casirivimab+imdevimab among 9000 people with severe COVID-19 |
Collaborator Contribution | Provision of casirivimab+imdevimab free of charge to trial sites |
Impact | Lancet publication Regulatory license applications globally. Change in clinical practice. |
Start Year | 2020 |
Description | RECOVERY-Roche |
Organisation | Roche Pharmaceuticals |
Country | Global |
Sector | Private |
PI Contribution | RECOVERY trial randomised assessment of tocilizumab for severe COVID-19. |
Collaborator Contribution | Tocilizumab provided to trial sites free of charge by Roche. |
Impact | Lancet publication. Supported Emergency Use Authorisation and regulatory license applications in over 50 countries to date. |
Start Year | 2020 |
Description | SHARP3 trial with BI |
Organisation | Boehringer Ingelheim |
Country | Germany |
Sector | Private |
PI Contribution | start-up agreement signed. We are designing (and will deliver) a trial of a novel agent to improve outcomes in patients with chronic kidney disease. |
Collaborator Contribution | trial collaborators |
Impact | n/a |
Start Year | 2022 |
Company Name | Quality BY Randomization Limited |
Description | |
Year Established | 2020 |
Impact | None as yet. |
Description | 19th Global Cardiovascular Clinical Trialists' Forum |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | 19th Global Cardiovascular Clinical Trialists' Forum |
Year(s) Of Engagement Activity | 2022 |
Description | 20th Congress of the International Society of Renal Nutrition and Metabolism |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | 20th Congress of the International Society of Renal Nutrition and Metabolism (Guangzhou/hybrid). Obesity, diabetes and cardiorenal mortality in Mexico. Talk to major international society about diabetes in Mexico |
Year(s) Of Engagement Activity | 2022 |
Description | ASCEND Dementia results |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | AHA presentation of the ASCEND Dementia results and associated media activity 15 Nov 2021 - Jane A |
Year(s) Of Engagement Activity | 2021 |
Description | ASCEND PLUS patient group meetings |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | Patient group meetings online on 17 June 2021 (NDPH panel), 26 July 2021 (Research for the Future panel, North of England [1]), 28 July 2021 (Research for the Future panel, North of England [2]), 8 September 2021 (Wales), 27 November 2021 (Scotland), 11 November 2021 (Centre for Ethnic Health Research, Leicester) - to discuss design of ASCEND PLUS trial Creation of ASCEND PLUS Patient Advisory Group; meetings on 6th Sept 2021 and 8th Feb 2022 |
Year(s) Of Engagement Activity | 2021 |
Description | Diabetes and Cardiovascular disease - the Mexican Experience |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Diabetes and Cardiovascular disease - the Mexican Experience. International Diabetes Federation Virtual Conference 2021 Masterclass. 8th December 2021. |
Year(s) Of Engagement Activity | 2021 |
Description | EMPA-KIDNEY results meeting |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Participant EMPA-KIDNEY results meeting for Oxford Kidney Unit (November 2022): presented results to trial participants |
Year(s) Of Engagement Activity | 2022 |
Description | ERA-EDTA Clinical Kidney Journal monthly podcast |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | ERA-EDTA Clinical Kidney Journal Monthly Podcast - podcast lead editor: (https://www.era-edta.org/en/education/ckj-journal-club-e-seminars/) - Mar 2021: The complexity of sleep disorders in dialysis patients - Apr 2021: Global Longitudinal Strain by Feature Tracking Cardiovascular MRI Predicts Mortality in Patients with End Stage Kidney Disease - May 2021: Eculizumab discontinuation in atypical haemolytic uremic syndrome: TMA recurrence risk and renal outcomes - June 2021: Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study - Sept 2021: Cycling during haemodialysis - results from PEDAL and CYCLE-HD - Oct 2021: Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics - Nov 2021: Monitoring anti-PLA2R antibody titres to predict the likelihood of spontaneous remission of membranous nephropathy - Jan 2022: Robot-assisted transplantation |
Year(s) Of Engagement Activity | 2021,2022 |
URL | https://www.era-edta.org/en/education/ckj-journal-club-e-seminars/ |
Description | Founder and editor of European Renal Association (ERA) Journal Club monthly 1-hour e-seminars x 3 |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Founder and editor of European Renal Association (ERA) Journal Club monthly 1-hour e-seminars x 3 |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.era-online.org/types/e-seminar/ |
Description | Genetic analyses link obesity to risk of kidney disease, so what can we do about it? |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Genetic analyses link obesity to risk of kidney disease, so what can we do about it? Kidney Research UK - Driving Discoveries: Celebrating our 60th anniversary. 21st October 2021. |
Year(s) Of Engagement Activity | 2021 |
Description | HRA Ethics Review Workshop |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Scientific adviser |
Year(s) Of Engagement Activity | 2020 |
Description | International Alport Research |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Talk to International Alport Research patient webinar about potential of SGLT-2 inhibitors in Alport Syndrome |
Year(s) Of Engagement Activity | 2021 |
Description | International Society of Nephrology Webinar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | An Encore Presentation of the EMPA-KIDNEY trial - virtual free talk for major international professional society |
Year(s) Of Engagement Activity | 2022 |
Description | Kidney Care UK webinars |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Webinar series for kidney patients |
Year(s) Of Engagement Activity | 2020,2021 |
Description | Kidney Disease Improving Global Outcomes (KDIGO) |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Working Group Member. Kidney Disease Improving Global Outcomes (KDIGO): Clinical Practice Guideline for the Evaluation & Management of CKD: 2024 Update. Section lead of Complications of CKD. Major international guideline group in kidney disease |
Year(s) Of Engagement Activity | 2021 |
URL | http://www.kdigo.org |
Description | Kidney Matters magazine interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | Kidney Matters magazine interview: Kidney Clinic: Protecting your kidneys with SGLT2 inhibitors: a landmark new treatment for CKD. Kidney Matters Issue 19: pp10-13 |
Year(s) Of Engagement Activity | 2022 |
Description | Kidney Research UK interview |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Kidney Research UK interview: Obesity research could help pinpoint treatments for some causes of kidney disease |
Year(s) Of Engagement Activity | 2022 |
Description | Late-breaking oral abstract: American Society of Nephrology Kidney Week 2022, Orlando, Florida. Empagliflozin in Chronic Kidney Disease. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Late-breaking oral abstract: American Society of Nephrology Kidney Week 2022, Orlando, Florida. Empagliflozin in Chronic Kidney Disease. |
Year(s) Of Engagement Activity | 2022 |
Description | MRC staff seminar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | April 2022: talk for MRC Staff Seminar |
Year(s) Of Engagement Activity | 2022 |
Description | Medscape Education Program on SGLT2 Inhibition in CKD Management (virtual). |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Medscape Education Program on SGLT2 Inhibition in CKD Management (virtual). Chapter 1: EMPA-KIDNEY results. Chapter 2: EMPA-KIDNEY in the context of previous major trials. Presentations for educational material for international online educator |
Year(s) Of Engagement Activity | 2022 |
Description | NHS Digitrials online engagement events |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | I November 2020 I took part in a series of Zoom events with members of the public to discuss NHS data policies |
Year(s) Of Engagement Activity | 2020 |
Description | NIHR & KRUK: UK Kidney Research Ecosystem |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation to NIHR and Kidney research UK invitees interested in renal trials in the UK: EMPA-KIDNEY presentation & discussant |
Year(s) Of Engagement Activity | 2023 |
Description | ORION-4 press announcement |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | I was involved in some of the press activity around the announcement of the ORION-17 trial, including answering questions for the BHF and the Sun |
Year(s) Of Engagement Activity | 2019 |
Description | Panel Discussant. Session 6: Contactless/decentralized/virtual trials/registry trials in CKD: challenges and opportunities |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Panel Discussant. Session 6: Contactless/decentralized/virtual trials/registry trials in CKD: challenges and opportunities. 6th Kidney Disease Clinical Trialists Workshop. 30th October 2021. |
Year(s) Of Engagement Activity | 2021 |
Description | RECOVERY Participant Panel |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | RECOVERY trial participant panel. |
Year(s) Of Engagement Activity | 2020,2021,2022 |
Description | RECOVERY Trial |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | National and international media coverage as a result of my involvement in the world's largest trial investigating COVID-19 treatments, the RECOVERY Trial |
Year(s) Of Engagement Activity | 2020,2021 |
URL | http://www.recoverytrial.net |
Description | SGLT-2 inhibitor guidelines in CKD. |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | SGLT-2 inhibitor guidelines in CKD. Proposer, chair and speaker for pop-up session at UK Kidney Week October 2021. |
Year(s) Of Engagement Activity | 2021 |
Description | SGLT-2 inhibitors - treatment for diabetic and nondiabetic kidney disease |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | SGLT-2 inhibitors - treatment for diabetic and nondiabetic kidney disease. Royal College of Edinburgh Renal Medicine Online Symposium. 22nd April 2021. |
Year(s) Of Engagement Activity | 2021 |
Description | SGLT-2 inhibitors - treatment for diabetic and nondiabetic kidney disease. |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | SGLT-2 inhibitors - treatment for diabetic and nondiabetic kidney disease. Royal College of Edinburgh Renal Medicine Online Symposium. 22nd April 2021. |
Year(s) Of Engagement Activity | 2021 |
Description | SGLT2i: an update for nephrologists |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | SGLT2i: an update for nephrologists. Clinical Research Network Kent, Surrey Sussex meeting. 13th October 2021 |
Year(s) Of Engagement Activity | 2021 |
Description | Trials and tribulations of research in nephrology: Historical perspective and hope for patients. |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Trials and tribulations of research in nephrology: Historical perspective and hope for patients. Special Session: Capacity Building: The need for dedicated training programs and innovative trial design. Virtual World Congress of Nephrology (WCN'21), April 15-19, 2021 |
Year(s) Of Engagement Activity | 2021 |
Description | UK Renal Trials Network update session |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | UK Renal Trials Network update session. Proposer and session main chair at UK Kidney Week. October 2021 |
Year(s) Of Engagement Activity | 2021 |
Description | UK Renal Trials Network update session. Proposer and session main chair at UK Kidney Week. October 2021 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | UK Renal Trials Network update session. Proposer and session main chair at UK Kidney Week. October 2021 |
Year(s) Of Engagement Activity | 2021 |
Description | World Congress of Nephrology: SGLT2 Inhibition From the Bench to Clinic |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | World Congress of Nephrology: SGLT2 Inhibition From the Bench to Clinic: All That You Need to Know Clinical Trials Data in Diabetic Nephropathy, Cardiovascular Disease, and Proteinuric CKD. Invited talk for Mar 2022 |
Year(s) Of Engagement Activity | 2022 |
Description | World Congress of Nephrology: SGLT2 Inhibition From the Bench to Clinic (virtual). |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | World Congress of Nephrology: SGLT2 Inhibition From the Bench to Clinic (virtual). All That You Need to Know Clinical Trials Data in Diabetic Nephropathy, Cardiovascular Disease, & Proteinuric CKD. Update on kidney trials for major international renal conference. |
Year(s) Of Engagement Activity | 2022 |
Description | a. Talk at Abingdon School on evidence in medicine |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | Talk at Abingdon School on evidence in medicine |
Year(s) Of Engagement Activity | 2022 |
Description | talk for Alzheimer's Research UK on RECOVERY |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | talk for Alzheimer's Research UK on RECOVERY and trials in dementia |
Year(s) Of Engagement Activity | 2022 |
Description | talk for Six Counties Kidney Patient Association on RECOVERY |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | talk for Six Counties Kidney Patient Association on RECOVERY |
Year(s) Of Engagement Activity | 2022 |